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THESIS ABSTRACT 
 
Coronary atherosclerosis and chronic obstructive pulmonary disease (COPD) are 
highly prevalent, and two of the commonest causes of morbidity and mortality in the 
Australian population. They share cigarette smoking as an important risk factor, and 
frequently coexist. Drugs which act on the beta-adrenergic receptor are important 
therapeutic tools in both diseases. However, beta-receptor antagonists, which are 
commonly used to treat cardiac disease, theoretically may cause adverse respiratory 
effects and are traditionally avoided in patients with obstructive airways disease. 
This work seeks to explore the short and longer term effects of beta-blocker 
medications, when used for treatment of cardiac disease in patients with coexisting 
obstructive airways disease. Specifically, the aims of this research are: 
 
1. To estimate the prevalence of coexisting obstructive airways disease amongst 
patients with cardiac disease 
2. To investigate current beta-blocker prescribing practice in patients with 
obstructive airways disease 
3. To document adverse respiratory effects of beta-blocker medications, in 
terms of symptoms, lung function and other longer term health outcomes. 
 
Within 24 hours of hospital admission for suspected cardiac disease, patients were 
screened for airways obstruction, using spirometry. Spirometry results demonstrated 
a high level of coexistence of cardiac disease and obstructive airways disease, about 
twice that cited in previously published estimates. Documentation of beta-blocker 
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prescribing practices within the Royal Prince Alfred Hospital’s Cardiology Unit 
revealed minimal prescription of these medications to patients with previously 
diagnosed chronic obstructive airways disease and asthma, despite limited evidence 
of adverse effects of beta-blocker use in such patients. This notably occurred even 
when guidelines recommended beta-blockade as first line therapy, and where 
survival benefit was established. However, many patients with obstructive 
spirometry, but no formal diagnosis of obstructive airways disease, did receive beta-
blockers. Longitudinal analysis of symptom assessment, lung function and health 
outcomes was performed. Lung function and respiratory symptoms data were 
collected over a twelve month period and data pertaining to beta-blocker 
discontinuation, respiratory exacerbations, acute cardiac events and survival were 
collected over almost six years. There was no indication of a statistically significant 
adverse beta-blocker effect on lung function, respiratory symptoms or survival but 
beta-blocker medications did appear to increase respiratory exacerbation rates.  
 
This work confirms the very high frequency of obstructive airways disease existing 
in combination with cardiac disease in an Australian urban population, which had 
been suspected but not previously documented. However, its major contribution is to 
provide prospective long term respiratory health outcome data for the use of beta-
blocker medications in this group.     
 
 
 
